GEN-MKT-18-7897-A
Nov 9, 2016 | Biopharma, Blogs | 0 comments
A variety of post-translational modifications (PTMs) can impact a biotherapeutic protein’s mass, but none are as common as glycosylation.[1] Hence, the headline for a recent article in Genetic Engineering and Biotechnology News, “Post-Translational Icing on the Biologics Cake,” featuring comments from Sean McCarthy, Ph.D., Global Market Manager of Biologics at SCIEX.
About the Article: Biotherapeutic protein glycosylation plays a key role in whether or not a biologic drug can effectively treat disease, making the detection and characterization of these glycan structures an important topic for pharmaceutical developers. Dr. McCarthy gives his take on using different liquid chromatography separation techniques together with mass spectrometry to go after low-level immunogenic glycan epitopes on biotherapeutics, which could elicit an undesirable immune response in patients. The development of focused instrumentation and software solutions to meet the needs of biologics characterization workflows are profiled in this article, with a focus on the SCIEX TripleTOF® 6600 MS system coupled with BioPharmaView™ software. Together, the TripleTOF system and BioPharmaView software can profile intact protein glycoforms, or comprehensively identify and quantitate specific glycopeptides.Read the Article >
Want to Know More about Glycan Analysis?
Discover innovations with this useful ‘Glycan Analysis Solution Guide’ that helps you:
About Dr. McCarthy:Sean M. McCarthy received his degree in Chemistry from the University of Vermont in 2005, followed by his NIH postdoctoral associate within the Department of Pathology at the same institution. His work centered on environmental oxidative stress related diseases using a variety of biochemical and mass spectrometric techniques. Dr. McCarthy has worked in the mass spectrometry industry since 2008 and has held several scientific and business development positions to address pharmaceutical and biopharmaceutical characterization. Dr. McCarthy is currently the Global Market Manager of Biologics at SCIEX, where his focus is on delivering targeted solutions for biopharmaceutical characterization.
[1] http://www.sciencedirect.com/science/article/pii/S135964461600026X
Regulated laboratories are evolving faster than ever. New analytical modalities, higher sample throughput, increasing regulatory scrutiny, and leaner teams are reshaping how work gets done. At the same time, expectations for data integrity, standardization, and operational efficiency continue to increase complexity and/or scope. In this environment, LC-MS software is no longer simply an instrument control platform—it has become a critical part of a laboratory’s quality management system. The question is no longer whether your lab has changed, but whether your software has evolved to support the way regulated labs operate today, and if they are ready and able to meet the demands, they will face tomorrow.
Analyst software has long been a trusted foundation in regulated LC-MS laboratories—and for many, it still performs reliably today. But regulated environments are evolving faster than ever. As labs transition to Windows 11, strengthen cybersecurity policies, modernize IT infrastructure, and prepare for future compliance expectations, software decisions are no longer just about what works today—they’re about managing tomorrow’s risk. Analyst will not be supported on Windows 11. While some labs may continue operating in unsupported environments temporarily, the bigger question is: when that risk becomes reality, will your lab be reacting under pressure—or executing a planned mitigation strategy with confidence?
As regulatory scrutiny increases and detection requirements tighten, laboratories are facing a new question: How can TFA be measured reliably, sensitively, and at scale?
Posted by
You must be logged in to post a comment.
Share this post with your network